title: CB1 receptor-dependent and -independent inhibition of excitatory postsynaptic currents in the hippocampus by WIN 55,212-2.
abstract: We investigated the effect of a synthetic cannabinoid, WIN 55,212-2 on excitatory postsynaptic currents (EPSCs) evoked by stimulation of Schaffer collaterals in CA1 pyramidal cells. Bath application of WIN 55,212-2 reduced the amplitude of EPSCs in dose-dependent manner tested between 0.01 nM and 30 microM. In rats and mice, this cannabinoid ligand inhibited excitatory synapses in two steps at the nM and muM concentrations. When the function of CB(1) cannabinoid receptors (CB(1)R) was impaired, either by the application of a CB(1)R antagonist AM251, or by using CB(1)R knockout mice, WIN 55,212-2 in microM concentrations could still significantly reduced the amplitude of EPSCs. WIN 55,212-2 likely affected the efficacy of excitatory transmission only at presynaptic sites, since both at low and high doses the paired pulse ratio of EPSC amplitude was significantly increased. The inactive enantiomer, WIN 55,212-3, mimicked the effect of WIN 55,212-2 applied in high doses. In further experiments we found that the CB(1)R-independent effect of 10 microM WIN 55,212-2 at glutamatergic synapses was fully abolished, when slices were pre-treated with omega-conotoxin GVIA, but not with omega-agatoxin IVA. These data suggest that, in the hippocampus, WIN 55,212-2 reduces glutamate release from Schaffer collaterals solely via CB(1)Rs in the nM concentration range, whereas in microM concentrations, WIN 55,212-2 suppresses excitatory transmission, in addition to activation of CB(1)Rs, by directly blocking N-type voltage-gated Ca(2+) channels independent of CB(1)Rs.
authors: Institute of Experimental Medicine, Hungarian Academy of Sciences, Szigony u. 43, Budapest H-1450, Hungary.
authors: Beáta
authors: B
authors: Németh
authors: Catherine
authors: C
authors: Ledent
authors: Tamás F
authors: TF
authors: Freund
authors: Norbert
authors: N
authors: Hájos
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D048588:Benzoxazines / Q000494:pharmacology*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004307:Dose-Response Relationship, Radiation; D004347:Drug Interactions; D004558:Electric Stimulation; D019706:Excitatory Postsynaptic Potentials / Q000187:drug effects*; D006624:Hippocampus / Q000166:cytology*; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D009025:Morpholines / Q000494:pharmacology*; D009281:Naphthalenes / Q000494:pharmacology*; D009433:Neural Inhibition / Q000187:drug effects; D009474:Neurons / Q000187:drug effects*; D018408:Patch-Clamp Techniques; D010880:Piperidines / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D051381:Rats; D043884:Receptor, Cannabinoid, CB1 / Q000172:deficiency / Q000378:metabolism*
chemical_list: D048588:Benzoxazines; D002121:Calcium Channel Blockers; D009025:Morpholines; D009281:Naphthalenes; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; C103505:AM 251; C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone
references: J Neurophysiol. 2000 Mar;83(3):1167-80
references: 10712447
references: J Neurosci. 2000 Apr 1;20(7):2470-9
references: 10729327
references: Eur J Neurosci. 2000 Sep;12(9):3239-49
references: 10998107
references: Br J Pharmacol. 2000 Oct;131(4):663-5
references: 11030713
references: J Neurosci. 2001 Jan 1;21(1):109-16
references: 11150326
references: J Neurophysiol. 2001 Jan;85(1):468-71
references: 11152748
references: J Physiol. 2001 May 1;532(Pt 3):731-48
references: 11313442
references: Neuron. 2001 Aug 16;31(3):453-62
references: 11516401
references: Neuroscience. 2001;106(1):1-4
references: 11564411
references: J Neurosci. 2001 Dec 15;21(24):RC188
references: 11734603
references: EMBO J. 2001 Dec 17;20(24):7033-40
references: 11742980
references: J Neurosci. 2002 May 15;22(10):3864-72
references: 12019305
references: Neuropharmacology. 2002 Sep;43(4):503-10
references: 12367597
references: Learn Mem. 2003 Mar-Apr;10(2):116-28
references: 12663750
references: J Neurosci. 2003 Jul 2;23(13):5906-18
references: 12843295
references: Physiol Rev. 2003 Jul;83(3):1017-66
references: 12843414
references: Eur J Neurosci. 2003 Aug;18(3):524-34
references: 12911748
references: Eur J Neurosci. 2003 Aug;18(4):1017-20
references: 12925027
references: Eur J Neurosci. 2003 Oct;18(7):1973-8
references: 14622229
references: Neuropharmacology. 2004 Jan;46(1):115-25
references: 14654103
references: Mol Pharmacol. 1995 Sep;48(3):443-50
references: 7565624
references: J Neurosci. 1996 Jul 15;16(14):4322-34
references: 8699243
references: Brain Res. 1998 Feb 2;783(1):77-84
references: 9479052
references: J Physiol. 1998 Aug 1;510 ( Pt 3):867-79
references: 9660899
references: J Neurosci. 1999 Jun 1;19(11):4544-58
references: 10341254
references: J Neurosci. 1999 Aug 15;19(16):6795-805
references: 10436037
references: J Neurosci. 2005 Mar 16;25(11):2874-84
references: 15772347
references: Eur J Neurosci. 2005 Nov;22(9):2387-91
references: 16262678
references: J Physiol. 2005 Dec 1;569(Pt 2):501-17
references: 16179366
references: Neuroscience. 2005;136(3):811-22
references: 16344153
references: Neuroscience. 2006;137(1):337-61
references: 16289348
references: J Neurosci. 2006 Mar 15;26(11):2991-3001
references: 16540577
references: Neuroscience. 2006;139(3):795-802
references: 16527424
references: J Neurosci. 2006 May 24;26(21):5628-37
references: 16723519
references: J Neurophysiol. 2006 Sep;96(3):1267-77
references: 16738209
references: Eur J Neurosci. 2007 Apr;25(8):2445-56
references: 17445240
references: Br J Pharmacol. 2007 Jun;151(4):551-63
references: 17435795
references: J Neurosci. 2006 May 24;26(21):5794-9
references: 16723537